Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека АбfiledCriticalАстразенека Аб
Priority claimed from PCT/EP2020/058360external-prioritypatent/WO2020200960A1/en
Publication of EA202192662A1publicationCriticalpatent/EA202192662A1/en
Изобретение относится к лечению астмы у субъекта-человека путем введения с помощью ингаляции терапевтически эффективного количества мутеина липокалина против рецептора IL-4 альфа (IL-4R) или его варианта или фрагмента указанному субъекту, при этом доставляемая доза указанного мутеина липокалина или его варианта или фрагмента составляет от около 0,1 до около 160 мг. Мутеин липокалина или его вариант или фрагмент можно, например, вводить по меньшей мере один раз в день, один раз в день или два раза в день.The invention relates to the treatment of asthma in a human subject by administering by inhalation a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4R) mutein or variant or fragment thereof to said subject, wherein the delivered dose of said lipocalin mutein or variant or fragment thereof is is from about 0.1 to about 160 mg. The lipocalin mutein, or variant or fragment thereof, may, for example, be administered at least once a day, once a day, or twice a day.
EA202192662A2019-09-262020-03-25
MUTEIN LIPOCALIN FOR THE TREATMENT OF ASTHMA
EA202192662A1
(en)
at least one chemical entity; pharmaceutical composition; use of a therapeutically effective amount of at least one chemical entity; packaged pharmaceutical composition
Methods of treating, controlling or preventing specific cancer and a disease associated with unwanted angiogenesis and of reducing or preventing an adverse effect associated with the administration of a second active ingredient and with radiation therapy, hormone therapy, biological therapy or immunotherapy in a patient suffering from a specific cancer, pharmaceutical composition and kit